Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Heatmap
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
CRDL
#3858
Cardiol Therapeutics Inc. Class A Common Shares
1.4
0
USD
+2.94%
Secteur:
Soins de Santé
Base:
USD
Devise de Profit:
USD
Range quotidien
Range Annuel
Changement quotidien
+2.94%
Changement Mensuel
+34.62%
Evolution sur 6 mois
+34.62%
Changement Annuel
+37.25%
Clôture Précédente
1.3
6
Open
1.4
0
Bid
Ask
Low
1.4
0
High
1.4
0
Volume
3
Marchés
Actions des Marchés US
Soins de Santé
CRDL
Open full chart
Financials
Overview
Relevé
Statistics
Quarterly
Annual
Value
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
64.04 M
65.35 M
82.61 M
100.26 M
312.26 M
Valuation ratios
Enterprise value
34.59 M
57.51 M
105.74 M
95.63 M
293.46 M
Price to earnings ratio
—
—
—
—
—
Price to sales ratio
—
—
—
—
—
Price to cash flow ratio
—
—
—
—
—
Price to book ratio
—
—
—
—
—
Enterprise value to EBITDA ratio
—
—
—
—
—
Profitability ratios
Return on assets %
—
—
—
—
—
Return on equity %
—
—
—
—
—
Return on invested capital %
—
—
—
—
—
Gross margin %
—
—
—
—
—
Operating margin %
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
Net margin %
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
Current ratio
—
—
—
—
—
Inventory turnover
—
—
—
—
—
Asset turnover
—
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
—
—
—
EBIT per share
—
—
—
—
—
EBITDA per share
—
—
—
—
—
Total debt per share
—
—
—
—
—
Cash per share
—
—
—
—
—
Net current asset value per share
—
—
—
—
—
Tangible book value per share
—
—
—
—
—
Working capital per share
—
—
—
—
—
Book value per share
—
—
—
—
—
Nouvelles
Le PDG de Cardiol Therapeutics évoquera les essais cliniques
Cordel étend son contrat avec Transport for London à la District line
Cardiol dépasse 50% d’enrôlement dans son essai de phase III sur la péricardite
Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards?
Cardiol Therapeutics publie les résultats de l’étude de phase II sur la myocardite
Cardiol Therapeutics publishes phase II myocarditis study results
Cardiol Therapeutics dépose un accord de souscription et un acte de garantie
Cardiol Therapeutics files underwriting agreement and warrant indenture
Cardiol Therapeutics annonce un placement privé de 13,5 millions $
Cardiol Therapeutics announces $13.5 million private placement
Cardiol Therapeutics annonce un financement par prise ferme de 13,5 millions $
Cardiol Therapeutics announces $13.5 million bought deal financing